Any thoughts on this company. Seemes to have good phase11 trail results in both their anti obesity drug and Irratable bowel syndrome drugs.
Much appreciated
Makes a change for a bio tech com to do well.
Thanks in advance

It hits 3 year high, will it continue rise or shall I sell it? Or hold it?

-- ckmtang,

You really really need to read that thread referenced in post 7. It's not on MAM, but will dramatically increase your knowledge if AZM. At the end of that, you should be in a good position to decide for yourself whether or not this will continue to rise or not. In fact, just the first post, and the other thread referenced from there will give a very good grounding.

still looking good the share.

why the share rise a bit in the morning hour?

Allegedly been a broker upgrade from Nomura - to 220p.

where you get this news?

Was posted by someone on Hemscott - I have no way of knowing if it's true or not. Can't see it on here

I still judging is it truth or not. But I can`t find anyhting from FT, IC, and elsewhere.

I still judging is it truth or not. But I can`t find anyhting from FT, IC, and elsewhere.

There was also news on BBC radio for te goverment to treat obesity as a illness

Me either - the poster concerned has been ramping hell out of AZM recently, so dunno if it's true. Probably is, though - someone on HS would have monstered him by now, if it was a lie

-- washlander,

I heard that, but it has the slight problem that it would require the government to spend money on it!

I note in passing that with the price at 179/181 (+16p/9.8%), I've just gone over +300% profit on these. :-D

Well that didn't last long - not surprising that the price is coming off a bit - tempted to take profit and look for another entry point on a retracement

the share rise a lot today.

but still can`t find the true news in anywhere.

Apparently from the FT - can't find the original story, but gist was posted on Advfn

"Alizyme rose 4.1 per cent to 164p yesterday, having tripled in value since the start of August.
The rally has been driven by positive news flow for both its obesity therapy ATL-962 and Renzapride, its treatment for irritable bowel syndrome. Alizyme is unusual for a biotech company in having three products ready for final clinical trials, making it more likely to produce a marketable product than many of its peers.
Further progress for the shares may depend on Alizymes's ability to tie-up licensing agreements with local partners, although it could opt to enhance its appeal as a takeover candidate by retaining commercialisation rights.
... Sam Fazeli of Nomura estimates a deal would bring in $20-$30m initially and forecasts peak sales of 718m by 2010 if the obesity product can launch commercially. Nomura is also forecasting peak sales of 510m by 2010 for IBS treatment if a Licensing agreement can be conducted before its patent expires in 2007.
The Japanese bank also has a "buy" recommendation and has raised its target price to 220p, despite not expecting Alizyme to deliver profits before 2006."

I took profits and will wait for retrenchment to go back in. If there is not to be a prob with obesity which in the long term will cause major drain on NHS resources then the goverment will have to act. As it is, it is a major prob in the US.

Back up again.

still looking good....... nearly touching 2 pound today morning

over 2.00 mark. Now it has broken this mark where will stop. any ideas?